The objective of the present research work was to develop a multi-particulate modified release system of Fenofibric acid using Wurster (Bottom spray fluid bed coating) process.
.
Fenofibrate is a third-generation fibric acid derivative indicated for the treatment of primary hyper-lipidemia or mixed dyslipidemia. Fenofibrate is a prodrug and requires enzymatic cleavage via first pass metabolism, hydrolysis at the ester bond to form fenofibric acid, which is the active metabolite. Insolubility of fenofibrate in water negatively impact the in vivo performance of the product. Hence, novel fenofibrate formulations were developed with different approaches to overcome the challenges with solubility, to prevent the recrystallization of drug in acidic pH and to improve bioavailability. Choline fenofibrate is a choline salt of fenofibric acid and is more hydrophilic than fenofibrate. It does not need first pass hepatic metabolism to become active, as it dissociates to free fenofibric acid within the gastrointestinal tract and rapidly absorbed throughout the gastrointestinal tract 6, 7 .
The present investigation aimed to fabricate a 
Materials and methods

Materials
Choline fenofibrate was obtained from RA CHEM Pharma Ltd., 
Methods
Drug-excepient compatibility studies
Choline fenofibrate and selected excipients were subjected for drug excipient compatibility study. The drug and individual excipients were intimately mixed in equal parts by weight and filled in glass vials stoppered with teflon plugs and sealed with aluminium seals. These samples were kept in incubators at 40°C/75%RH. Samples were analyzed for the solid state property of the drug in the blended mixtures was ascertained using differential scanning colorimeter (DSC) at initial and one month (40°C/75%RH).
Preparation of Fenofibric acid Delayed Release (DR)
Pellets by Wurster process
Fenofibric acid DR Pellets were prepared by employing bottom -spray fluid bed (Wuster) coating process (Glatt GPCG 1.1).
The dosage form was designed to obtain the delayed extended release. Drug loaded pellets were prepared by spraying the aqueous drug dispersion over non pariel seeds (Sugar spheres Further, the aqueous enteric coating dispersion was coated on to the ER coated pellets at 28-32°C as product temperature and at a spray rate of 2-6g/min. Enteric coated pellets were subjected for drying at 35°C for 15 minutes. Final pellets were sifted through #14-#18 ASTM mesh to separate the fines and agglomerates and collects the desired portion.
Experimental design
In preliminary trials, the formulation variables in each step of the manufacturing process were evaluated for their significance by 
Optimization of ER coating composition
The independent variables in extended release coating were 
Evaluation of Fenofibric acid DR pellets
Micromeritic properties 9
Bulk density (BD), tapped density (TD) and Hausner ratio (HR) of pellets were determined. BD and TD were determined by USP method I using a Tapped density tester.
Bulk density = Weight of the sample (g)/ Untapped volume (ml)
Tapped density = Weight of the sample (g)/ Tapped volume (ml)
Hausner ratio were calculated using following formulae
Hausner ratio = TD / BD Where, TD and BD are tapped and bulk densities. 
Assay
Drug release kinetics 11
The drug release kinetics and mechanism from the formulations were studied by fitting the data obtained from the in vitro release study into several mathematical equations.
Results and Discussions
Drug excepient compatibility studies
From the DSC thermograms, at the initial stage, the onset melting point of API and composite blend were observed at 215.15ºC& 178.17 ºC, respectively and peak melting point of API and composite blend were observed at 218.01 ºC and 186.66 ºC, respectively. The endothermic peaks after 4 weeks storage at 40 °C/75%RH, the onset melting point of API and composite blend were observed at 214.09 ºC &176.01 ºC, respectively and peak melting point of API and composite blend were observed at 216.43 ºC and 185.88 ºC, respectively (Fig 1) .
Hence, it was concluded that there was no interaction between the drug substance and the chosen excipients. Hence these excipients were considered for the use in the development of the formulation. Hence these factors were studied at three levels employing face centered central composite design. shown a positive impact on Y2, whereas A and B 2 have a negative impact on Y2.
Preparation of pellets
Data analysis and model validation 3.3.1 Fitting of data to the model
Contour and three dimensional response surface plot analysis
The design expert software (Stat-Ease) generated the contour, and three dimensional surface plots are presented in Fig 2 and 3, which are very useful to study the interaction effects of the factors on responses. This type of the plot visualizes the effects of two factors on the response at a time. 
Optimization
A numerical optimization technique using the desirability function approach was employed to generate the optimum concentration of the independent variables. Suitable levels of constraints were choosen to achieve desired results of the formulation. It was found to satisfy the requisites of an optimum batch when the desirable ranges of responses were restricted % drug release at 2.5 th h to 12 % -22% and % drug release at 6 th h to > 75% (75% -100%). On analyzing various response variables and comprehensive evaluation of feasibility of exhaustive grid search, the following combination variable was suggested by the software with desirability function of 0.805 as reported in Table 3 , is closer to 1. The optimized formulation has shown a drug release at both 2.5 th h and 6 th h well within the predetermined specifications. The drug release profile of optimized formulation is presented in Fig 4. Hence, it was suggested that the generated models were well suited to optimization of the Fenofibric acid DR pellets.
Evaluation of pellets
Micromeretic properties
The bulk and tapped density of batches ranges from 0.64 -0.69 g/cc &0.67 -0.71 g/cc respectively. The Hausner's ratio values 
Assay
The assay of the all formulations was tested and results were found in the range of 98.9-101.1%. Assay of the optimized formulation was observed to be 100.1%.
Drug release kinetics
The dissolution data of optimized formulation fitted into kinetic models, the obtained results concluded that the drug release followed the first order kinetics as r 2 values were higher for first order model (0.954) than zero order model (0.847). The n value is greater than 0.45 (0.580); hence the mechanism of drug release was non-fickian diffusion. The optimized batch showed 100.1% assay and drug release was well within the predetermined specifications.
Micromeritic properties of these pellets exhibited excellent flow properties, which are crucial to attain the uniformity of dosage units in capsule filling. DSC studies evidenced that there was no interaction between drug and selected excipients. The optimized formulation can be used as an alternative to the marketed formulation. Hence, the applicability of response surface methodology to optimize the formulation variables in the fabrication of Fenofibric acid DR pellets is apt enough.
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